IRENE NEVAREZ: Open Payments
NPI 1003166646 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,490 in 54 payments from 11 companies in 2025. Trend: 2023 $944 · 2024 $452 · 2025 $1,490
Food & beverage: $1,378Education: $111
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 7 | $247 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $239 |
| Neurocrine BioSciences, Inc. | 9 | $236 |
| Teva Pharmaceuticals USA, Inc. | 6 | $232 |
| Alkermes, Inc. | 10 | $211 |
| Otsuka America Pharmaceutical, Inc. | 5 | $121 |
| ABBVIE INC. | 3 | $74 |
| Supernus Pharmaceuticals, Inc. | 2 | $47 |
| Janssen Pharmaceuticals, Inc | 2 | $43 |
| Lundbeck LLC | 1 | $21 |
Products named: FANAPT, CAPLYTA, INGREZZA, ARISTADA, UZEDY, REXULTI, VRAYLAR, Qelbree.
Industry payments across CA — which companies pay providers there.
